---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-033402"
form_type: "8-K"
ticker: "BAX"
cik: "0000010456"
company_name: "BAXTER INTERNATIONAL INC"
filed_at: "2023-10-02T23:59:59+00:00"
generated_at: "2026-06-10T06:13:44.155697+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Baxter completes sale of BioPharma Solutions business for $4.25B in cash

## Summary
- Closed sale of Baxter Pharmaceutical Solutions LLC and Baxter Oncology GmbH to Bamboo BidCo entities for $4.25B.
- Net pre-tax cash proceeds of approximately $3.96B received at closing.
- Company plans to use ~$3.4B of net after-tax proceeds to pay down debt through H1 2024.
- Prior full-year 2023 guidance scenario assuming no transaction is now withdrawn; only scenario with close remains.

## SEC filing metadata
- accession: 0001628280-23-033402
- form_type: 8-K
- ticker: BAX
- cik: 0000010456
- company_name: BAXTER INTERNATIONAL INC
- filed_at: 2023-10-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.01, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/10456/000162828023033402/0001628280-23-033402-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/10456/000162828023033402/bax-20230929.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-033402
- JSON: https://secwatch.observer/filing/0001628280-23-033402.json
- Plain text: https://secwatch.observer/filing/0001628280-23-033402.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.